Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCY-0098 in Recent Onset Type 1 Diabetes
NCT03272269Phase 1Completed
- Sponsor
- Imcyse
- Start
- Aug 2017
- Primary completion
- Apr 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Peptides
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial of imcy-0098 in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Imcyse. Primary endpoint: Incidence of all adverse events reported for subjects at 24 weeks. Started Aug 2017; status: completed.
02
Drugs
imcy-0098
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03272269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272269.